S&P 500   3,388.34 (-2.22%)
DOW   27,571.63 (-2.70%)
QQQ   278.42 (-2.22%)
AAPL   113.82 (-1.06%)
MSFT   209.69 (-3.02%)
FB   275.88 (-3.13%)
GOOGL   1,577.11 (-3.42%)
AMZN   3,182.00 (-0.70%)
TSLA   415.00 (-1.34%)
NVDA   523.95 (-3.62%)
BABA   305.60 (-1.39%)
CGC   18.76 (-4.92%)
GE   7.35 (-3.67%)
MU   51.62 (-2.33%)
AMD   81.75 (-0.26%)
T   27.26 (-2.01%)
F   7.99 (-2.08%)
ACB   4.43 (-5.34%)
GILD   59.71 (-1.78%)
NFLX   482.20 (-1.25%)
NIO   25.92 (-4.57%)
BA   160.43 (-4.14%)
DIS   123.78 (-3.56%)
S&P 500   3,388.34 (-2.22%)
DOW   27,571.63 (-2.70%)
QQQ   278.42 (-2.22%)
AAPL   113.82 (-1.06%)
MSFT   209.69 (-3.02%)
FB   275.88 (-3.13%)
GOOGL   1,577.11 (-3.42%)
AMZN   3,182.00 (-0.70%)
TSLA   415.00 (-1.34%)
NVDA   523.95 (-3.62%)
BABA   305.60 (-1.39%)
CGC   18.76 (-4.92%)
GE   7.35 (-3.67%)
MU   51.62 (-2.33%)
AMD   81.75 (-0.26%)
T   27.26 (-2.01%)
F   7.99 (-2.08%)
ACB   4.43 (-5.34%)
GILD   59.71 (-1.78%)
NFLX   482.20 (-1.25%)
NIO   25.92 (-4.57%)
BA   160.43 (-4.14%)
DIS   123.78 (-3.56%)
S&P 500   3,388.34 (-2.22%)
DOW   27,571.63 (-2.70%)
QQQ   278.42 (-2.22%)
AAPL   113.82 (-1.06%)
MSFT   209.69 (-3.02%)
FB   275.88 (-3.13%)
GOOGL   1,577.11 (-3.42%)
AMZN   3,182.00 (-0.70%)
TSLA   415.00 (-1.34%)
NVDA   523.95 (-3.62%)
BABA   305.60 (-1.39%)
CGC   18.76 (-4.92%)
GE   7.35 (-3.67%)
MU   51.62 (-2.33%)
AMD   81.75 (-0.26%)
T   27.26 (-2.01%)
F   7.99 (-2.08%)
ACB   4.43 (-5.34%)
GILD   59.71 (-1.78%)
NFLX   482.20 (-1.25%)
NIO   25.92 (-4.57%)
BA   160.43 (-4.14%)
DIS   123.78 (-3.56%)
S&P 500   3,388.34 (-2.22%)
DOW   27,571.63 (-2.70%)
QQQ   278.42 (-2.22%)
AAPL   113.82 (-1.06%)
MSFT   209.69 (-3.02%)
FB   275.88 (-3.13%)
GOOGL   1,577.11 (-3.42%)
AMZN   3,182.00 (-0.70%)
TSLA   415.00 (-1.34%)
NVDA   523.95 (-3.62%)
BABA   305.60 (-1.39%)
CGC   18.76 (-4.92%)
GE   7.35 (-3.67%)
MU   51.62 (-2.33%)
AMD   81.75 (-0.26%)
T   27.26 (-2.01%)
F   7.99 (-2.08%)
ACB   4.43 (-5.34%)
GILD   59.71 (-1.78%)
NFLX   482.20 (-1.25%)
NIO   25.92 (-4.57%)
BA   160.43 (-4.14%)
DIS   123.78 (-3.56%)
Log in
NYSE:QGEN

Qiagen Stock Forecast, Price & News

$48.88
-0.93 (-1.87 %)
(As of 10/26/2020 02:10 PM ET)
Add
Compare
Today's Range
$48.54
Now: $48.88
$49.13
50-Day Range
$46.98
MA: $51.26
$54.74
52-Week Range
$28.70
Now: $48.88
$55.27
Volume26,045 shs
Average Volume1.74 million shs
Market Capitalization$11.13 billion
P/E Ratio1,629.33
Dividend YieldN/A
Beta0.31
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, an application for analysis and interpretation of human sequencing data generated with next-generation sequencing (NGS) technologies; QIAGEN Clinical Insight, an evidence-based variant classification; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and order bioinformatics solutions and linking biological interpretation from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; QIAsymphony SP for sample preparation; QIAsymphony AS for assay setup; Rotor-Gene Q, a rotary real-time PCR cycler system; QIAstat-Dx for molecular analysis of common syndromes; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; NeuMoDx 288 and NeuMoDx 96 for automation of higher-throughput PCR testing in clinical laboratories; and QIAcube and QIAcube connect workstations, which provides versatile solutions for automated sample processing; It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has collaboration agreements with Ares Genetics and Laboratory Corporation of America Holdings. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Read More
Qiagen logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone31-77-355-6600
Employees5,096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.53 billion
Cash Flow$2.48 per share
Book Value$11.14 per share

Profitability

Net Income$-41,460,000.00

Miscellaneous

Market Cap$11.13 billion
Next Earnings Date11/4/2020 (Confirmed)
OptionableOptionable
$48.88
-0.93 (-1.87 %)
(As of 10/26/2020 02:10 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Qiagen (NYSE:QGEN) Frequently Asked Questions

How has Qiagen's stock price been impacted by COVID-19 (Coronavirus)?

Qiagen's stock was trading at $41.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, QGEN shares have increased by 18.5% and is now trading at $48.70.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Qiagen?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 9 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Qiagen
.

When is Qiagen's next earnings date?

Qiagen is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Qiagen
.

How were Qiagen's earnings last quarter?

Qiagen NV (NYSE:QGEN) released its quarterly earnings data on Tuesday, August, 4th. The company reported $0.55 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $0.55. The firm had revenue of $443.30 million for the quarter, compared to analyst estimates of $441.80 million. Qiagen had a return on equity of 15.85% and a net margin of 0.86%. Qiagen's revenue was up 16.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.34 earnings per share.
View Qiagen's earnings history
.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its third quarter earnings guidance on Tuesday, October, 13th. The company provided earnings per share guidance of ~$0.58 for the period, compared to the Thomson Reuters consensus estimate of $0.56. The company issued revenue guidance of $481.3 million, compared to the consensus revenue estimate of $462.67 million.

What price target have analysts set for QGEN?

19 brokerages have issued twelve-month target prices for Qiagen's shares. Their forecasts range from $36.00 to $66.00. On average, they expect Qiagen's share price to reach $51.28 in the next year. This suggests a possible upside of 5.3% from the stock's current price.
View analysts' price targets for Qiagen
.

Are investors shorting Qiagen?

Qiagen saw a decline in short interest during the month of September. As of September 30th, there was short interest totaling 3,460,000 shares, a decline of 19.9% from the September 15th total of 4,320,000 shares. Based on an average daily volume of 1,470,000 shares, the short-interest ratio is currently 2.4 days. Currently, 1.5% of the shares of the company are sold short.
View Qiagen's Short Interest
.

Who are some of Qiagen's key competitors?

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Paypal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

Who are Qiagen's key executives?

Qiagen's management team includes the following people:
  • Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 53)
  • Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 50)
  • Dr. Barthold Piening, Sr. VP & Head of Global Operations (Age 61)
  • Mr. John Gilardi, VP of Corp. Communications & Investor Relations
  • Mr. Jean-Pascal Viola, Head of Corp. Bus. Devel., Intellectual Property & Litigation and Sr. VP

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are Qiagen's major shareholders?

Qiagen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sycomore Asset Management (0.04%), Exane Derivatives (0.03%), Exane Derivatives (0.03%), Harvest Management LLC (0.02%), Crossmark Global Holdings Inc. (0.01%) and Tower View Investment Management & Research LLC (0.01%).

Which institutional investors are selling Qiagen stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including Sycomore Asset Management, Harvest Management LLC, and Crossmark Global Holdings Inc..

Which institutional investors are buying Qiagen stock?

QGEN stock was bought by a variety of institutional investors in the last quarter, including Exane Derivatives, Exane Derivatives, Tower View Investment Management & Research LLC, Diversified Trust Co, Campbell & CO Investment Adviser LLC, World Asset Management Inc, Bellecapital International Ltd., and IBM Retirement Fund.

How do I buy shares of Qiagen?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $48.70.

How big of a company is Qiagen?

Qiagen has a market capitalization of $11.09 billion and generates $1.53 billion in revenue each year. The company earns $-41,460,000.00 in net income (profit) each year or $1.43 on an earnings per share basis. Qiagen employs 5,096 workers across the globe.

What is Qiagen's official website?

The official website for Qiagen is www.qiagen.com.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.